EcoDrugPlus

Adrenoceptor Alpha 2c

Ensembl ID : ENSMZEG00005010586
Gene Symbol: ADRA2C
1 Cross references
160 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSMZEG00005021797
Gene Symbol: ADRA2C
4 Cross references
157 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSMZEG00005000756
Gene Symbol: ADRB2
3 Cross references
192 Possible Orthologues:

Aldose Reductase

Ensembl ID : ENSMZEG00005011270
Gene Symbol: LOC101477205
3 Cross references
343 Possible Orthologues:

Aldose Reductase

Ensembl ID : ENSMZEG00005011254
Gene Symbol: LOC101477496
3 Cross references
345 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSMZEG00005003163
Gene Symbol: GAA
3 Cross references
234 Possible Orthologues:

Alpha-1a Adrenergic Receptor

Ensembl ID : ENSMZEG00005012302
Gene Symbol: LOC101485219
3 Cross references
191 Possible Orthologues:

Alpha-1a Adrenergic Receptor

Ensembl ID : ENSMZEG00005010901
Gene Symbol: LOC101475209
3 Cross references
202 Possible Orthologues:

Alpha-2b Adrenergic Receptor

Ensembl ID : ENSMZEG00005009366
Gene Symbol: LOC101484392
3 Cross references
174 Possible Orthologues:

Alpha-Synuclein

Ensembl ID : ENSMZEG00005019652
Gene Symbol: LOC101468074
2 Cross references
189 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSMZEG00005015479
Gene Symbol: AOC1
3 Cross references
231 Possible Orthologues:

Amine Oxidase Copper Containing 2

Ensembl ID : ENSMZEG00005008657
Gene Symbol: AOC2
1 Cross references
403 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).